News Breaks |
|
|
| September 19, 2012 |
| 06:10 EDT |  | ABT, BSX, JNJ, COV, LMCA, NWSA, AAMRQ | On the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: The Bank of Japan decided on strong steps to further ease its monetary policy today following recent easing action by the Fed, as the central bank looks to tackle entrenched deflation, the strong yen, and slowing global growth, the Wall Street Journal reports...Research that suggests prescription drugs are as good or better at preventing strokes than interventional procedures is prompting a range of leading doctors to recommend against carotid surgery and carotid stent implants in most patients who haven't had stroke symptoms. The shift has broad implications for large medical-device makers (ABT, BSX, JNJ, COV), the Wall Street Journal reports...REUTERS: Anschutz Co. said it wants to sell its sports and entertainment unit in a potential multi-billion dollar sale. Potential buyers could include Liberty Media Corp. (LMCA) and News Corp. (NWSA), Reuters reports...American Airlines (AAMRQ) said it notified over 11,000 workers they could lose their jobs as part of its bankruptcy reorganization, and that it was reducing flights 1% to 2% for the rest of September and October, Reuters reports...BLOOMBERG: Richmond Fed President Jeffrey Lacker said the shock from the credit crisis may impede efforts by the central bank to quickly bring down unemployment even with the use of record stimulus, Bloomberg reports...Johnson & Johnson (JNJ) is setting up four centers around the world to look for early-stage acquisitions, partnerships and investment opportunities, Bloomberg reports. |
|
|
News For ABT;BSX;JNJ;COV;LMCA;NWSA;AAMRQ From The Last 14 Days Check below for free stories on ABT;BSX;JNJ;COV;LMCA;NWSA;AAMRQ the last two weeks. |
|
|
| May 24, 2013 |
| 17:26 EDT |  | NWSA | News Corp. to take $1.2B-$1.4B charge in Q4 related to publishing segment
 Subscribe for More Information |
|
| 17:08 EDT | | LMCA | Berkshire Hathaway reports 5.03% passive stake in Starz
|
|
| 16:58 EDT | | AAMRQ | Outgoing AMR Corp. CEO's pay opposed by DoJ, Reuters says
AMR Corp.'s (AAMRQ) outgoing CEO Tom Horton's severance pay of nearly $20M allotted as part of the company's plan to emerge from bankruptcy and merge with US Airways (LCC) is being opposed by the Department of Justice, which says the deal violates bankruptcy law, reports Reuters. Reference Link |
|
| 15:07 EDT | | NWSA | Yahoo submits bid for Hulu, AllThingsD reports
Subscribe for More Information |
|
| 14:44 EDT |  | NWSA | News Corp. management to meet with JPMorgan
Subscribe for More Information |
|
| 13:19 EDT | | NWSA | KKR, Silver Lake to join bidding for Hulu video service, Bloomberg reports
|
|
| 08:38 EDT | | NWSA | News Corp. adopts stockholder rights plan ahead of split up
News Corporation and the new News Corporation announced that, in advance of their planned separation, the Board of Directors of the company and the current Board of the new News Corporation has each determined to adopt stockholder rights agreements for the company and for new News Corporation, respectively. The rights agreements would expire one year after the date of this announcement, in the case of the company, or one year after the date of the separation, in the case of the new News Corporation. The company said it has considered that there may be significant volume of trading in shares of 21st Century Fox and the new News Corporation around the time of the separation, and for a period thereafter. The rights agreements are intended to protect the stockholders of the company and the new News Corporation from efforts to obtain control of such companies that their respective Boards of Directors determine are not in the best interests of the companies and their respective stockholders, News Corp. said. |
|
| 08:35 EDT | | NWSA | News Corp. board approves separation of businesses, stock buyback after split
News Corporation announced that the separation of News Corporation into two distinct publicly traded companies, 21st Century Fox and the new News Corporation, has been formally approved by the company’s Board of Directors. The company also announced appointments to the Boards of Directors of both companies, effective upon the completion of the separation, which is expected to occur on June 28. In connection with the separation, the company’s Board has approved the distribution of all shares of the new News Corporation to the company’s stockholders in a ratio of one share of the new News Corporation for every four shares of News Corporation. Furthermore, the Board authorized a $500M stock repurchase program for the new News Corporation following completion of the separation. |
|
| 07:54 EDT |  | JNJ | Johnson & Johnson drug business should maintain momentum, says Wells Fargo
After attending J&J's bi-annual pharmaceutical business review, Wells Fargo believes that the revenue generated by four of the company's new drugs could double from 2012 to 2015. The firm thinks the company's pharmaceutical unit has one of the best growth outlooks in the sector, and it keeps an Outperform rating on the stock. |
|
| 07:11 EDT | | NWSA | Hulu attracts several bidders, Reuters reports
Subscribe for More Information |
| |
| 07:05 EDT | | COV | Covidien approves separation of Pharma business, declares Mallinckrodt dividend
Covidien announced that its board of directors has approved the separation of the Pharmaceuticals business from the rest of Covidien. For every eight ordinary shares of Covidien held, Covidien shareholders will receive one ordinary share of Mallinckrodt plc. No fractional shares of Mallinckrodt will be issued. Shareholders will receive cash in lieu of fractional shares. The distribution is expected to occur on June 28, to Covidien shareholders of record as of the close of business on June 19. After the distribution, Mallinckrodt will be an independent publicly traded company and Covidien will retain no ownership interest in Mallinckrodt. Mallinckrodt ordinary shares are expected to begin “regular way” trading on July 1, on the New York Stock Exchange under the ticker symbol "MNK." Covidien will continue to trade on the NYSE under the ticker symbol "COV." Covidien currently expects that “when-issued” trading for both Mallinckrodt and Covidien on the NYSE will begin on June 17. |
|
| 07:01 EDT | | COV | Covidien approves separation of Pharma business, declares Mallinckrodt dividend
|
|
| 06:28 EDT | | JNJ | Johnson & Johnson price target raised to $94 from $88 at Leerink
Subscribe for More Information |
|
| 06:10 EDT | | NWSA | On the Fly: Periodicals Wrap-Up
Subscribe for More Information |
|
| May 23, 2013 |
| 15:39 EDT | | NWSA | News Corp. to host investor day
Subscribe for More Information |
|
| 10:08 EDT |  | JNJ | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:31 EDT | | JNJ | Janssen expects to have more than 25 brand line extensions by 2017
Subscribe for More Information |
|
| 06:29 EDT | | JNJ | Johnson & Johnson coverage assumed with an Underperform at Credit Suisse
Subscribe for More Information |
|
| May 22, 2013 |
| 16:00 EDT |  | JNJ | Options Update; May 22, 2013
Subscribe for More Information |
|
| 12:22 EDT | | BSX | Boston Scientific says new data shows blood pressure reduction with Vessix
Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. |
| |
|
|
|
|
